布地格福吸入气雾剂与布地奈德福莫特罗粉吸入剂对缓解期慢阻肺患者肺功能以及生活质量影响的对照研究

目的探究布地格福吸入气雾剂与布地奈德福莫特罗粉吸入剂对缓解期慢性阻塞性肺疾病(Chronic obstructive pulmonary disease,COPD)患者的肺功能及健康相关生活质量(Health-related quality of life,HRQoL)的影响。方法选取2020年9月至2021年2月入住我院的200例在前一年经历至少1次急性加重的COPD患者,将患者随机分为布地奈德福莫特罗组及布地格福组,每组100例,分别每天接受布地奈德福莫特罗粉吸入剂或布地格福吸入气雾剂治疗,持续24周。比较两组治疗前以及治疗24周后肺通气功能即第1秒用力呼气容积(FEV1)/用力肺活量(FVC)和FEV1占预计值百分比(FEV1%pred)、圣乔治问卷(Saint George′s Respiratory Questionnaire,SGRQ)评分及急救药物(沙丁胺醇)使用情况。结果纳入187例患者(平均年龄69.47岁,68.45%为男性患者),布地格福组97例,布地奈德福莫特罗组90例。两组患者治疗前SGRQ评分、FEV1%pred值、FEV1/FVC值和临时使用沙丁胺醇次数差异无统计学意义(P>0.05)。分别治疗24周后,两组患者FEV1%pred,FEV1/FVC高于治疗前,SGRQ评分以及临时使用沙丁胺醇次数低于治疗前,差异均有统计学意义(P<0.05),且与布地奈德福莫特罗组相比,布地格福组以上指标改善更明显(P<0.05)。结论对于缓解期COPD患者,布地格福与布地奈德福莫特罗在24周均可以改善肺功能和HRQoL,但布地格福组改善更加显著。

Clinical controlled study of Budesonide/Glycopyrronium /Formoterol and Budes-onide and Formoterol on lung function and quality of life in COPD patients in re- mission

Objective To study the effects of Budesonide,glycopyrronium bromide and formoterol fumarate(BGF)inhalation aerosol and Budesonide and formoterol fumarate(BF)powder for Inhalation on lung function and health-related quality of life(HRQoL)in patients with chronic obstructive pulmonary disease(COPD)at remission period.Methods Totally 200 COPD patients treated in our hospital from September 2020 to February 2021 who had experienced more than once acute exacerbation in the previous year were chosen and divided into BGF group and BF group by using random number table method,100 cases in each group,who received BGF or BF treatment daily for 24 weeks.The lung ventilation functionForced expiratory volume in the first second(FEV1)/Forced vital capacity(FVC),FEV1 as a percentage of predicted value(FEV1%pred)],St.George′s Questionnaire(SGRQ)Score and use of emergency medicines(salbutamol)of the two groups before treatment and after 24 weeks later of treatment were compared.Results A total of 187 patients(mean age 69.47 years;68.45%male)were enrolled,97 in the BGF group,and 90 in BF group.There was no significant difference in SGRQ,FEV1%pred,FEV1/FVC or the number of temporary salbutamol use between the two groups before treatment(P>0.05).After 24 weeks of treatment,the FEV1%pred,FEV1/FVC of the two groups were increased,while the SGRQ score and the number of temporary salbutamol use were decreased,the differences being statistically significant(P<0.05);the improvement in the above indicators in BGF group was better than that in BF group(P<0.05).Conclusion In patients with COPD at remission period,both BGF amd BF can improve lung function and HRQoL within 24 weeks,but the effect of BGF is more significant.